<DOC>
	<DOCNO>NCT00676819</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate pharmacodynamic / pharmacokinetic property insulin aspart human soluble insulin different elderly ( 65 year age old ) type 2 diabetes .</brief_summary>
	<brief_title>Comparison Pharmacodynamics Pharmacokinetics Insulin Aspart Human Insulin Elderly People With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 2 diabetes Duration diabetes least 12 month Current treatment human insulin insulin analogue least 6 month BMI equal 35 kg/m2 HbA1c equal great 10.0 % No clinically significant cardiovascular event judge Investigator within last 6 month prior study History illness , opinion Investigator might confound result study pose additional risk administer trial product subject Current treatment systemic corticosteroid Any positive reaction drug abuse alcohol screen Cardiac problem define : decompensated heart failure and/or angina pectoris Uncontrolled treated/untreated hypertension judge Investigator blood pressure &gt; 180 mm Hg systolic and/or &gt; 110 mm Hg diastolic Known suspect allergy trial product relate product Blood donation 500 ml within last 12 week The receipt investigational drug within 4 week prior trial</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>